51672-U
Ascentis® Express 90Å C8 (2 μm) HPLC Columns
L × I.D. 7.5 cm × 3 mm UHPLC Column
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
UNSPSC Code:
41115700
NACRES:
SB.52
L × i.d.:
7.5 cm × 3 mm
Particle size:
2 μm
Matrix active group:
dimethyloctyl phase
Pore size:
90 Å pore size
Matrix:
Fused-Core particle platform, superficially porous particle
产品名称
Ascentis® Express C8, 2 μm UHPLC Column, 2 μm particle size, L × I.D. 7.5 cm × 3 mm
material
stainless steel column
Quality Level
agency
suitable for USP L7
product line
Ascentis®
feature
endcapped
manufacturer/tradename
Ascentis®
packaging
1 ea of
parameter
1000 bar max. pressure (14500 psi), 60 °C temp. range
technique(s)
LC/MS: suitable, UHPLC-MS: suitable, UHPLC: suitable
L × I.D.
7.5 cm × 3 mm
surface area
120 m2/g
impurities
<5 ppm (metals)
matrix
Fused-Core particle platform, superficially porous particle
matrix active group
dimethyloctyl phase
particle size
2 μm
pore size
90 Å pore size
pH
2-9
application(s)
food and beverages
separation technique
reversed phase
General description
Ascentis® Express 2μm C8 UHPLC columns are based on a 90 Å Fused-Core® particle design. The Fused-Core particle provides a thin porous shell of high-purity silica surrounding a solid silica core. This particle design exhibits very high column efficiency due to the shallow diffusion paths in the 0.4-micron thick porous shell and the small overall particle size of 2-microns. The densely bonded, extensively endcapped dimethyloctyl stationary phase of Ascentis Express 2μm C8 provides a stable, reversed-phase packing that can be used for basic, acidic, or neutral compounds.
Legal Information
Ascentis is a registered trademark of Merck KGaA, Darmstadt, Germany
Fused-Core is a registered trademark of Advanced Materials Technology, Inc.
法规信息
新产品
此项目有
商品
When a C18 doesn′t give the desired separation, or your sample contains compounds that are known to be difficult to retain or resolve on a C18, consider changing to an Ascentis® Express C8 column.
相关内容
Ascentis® Express 2.0 μm C8 Column Care & Use Sheet
Sreenivasa Rao Chitturi et al.
Journal of pharmaceutical and biomedical analysis, 55(1), 31-47 (2011-02-15)
This paper proposes a simple and selective RP-HPLC method for the determination of process impurities and degradation products (degradants) of atazanavir sulfate (ATV) drug substance. Chromatographic separation was achieved on Ascentis(®) Express C8, (150mm×4.6mm, 2.7μm) column thermostated at 30°C under
Ugandar Reddy Inugala et al.
Journal of chromatographic science, 51(5), 453-459 (2012-10-13)
This paper describes the development of a rapid, novel, stability-indicating gradient reversed-phase high-performance liquid chromatographic method and associated system suitability parameters for the analysis of naproxcinod in the presence of its related substances and degradents using a quality-by-design approach. All
Luigi Silvestro et al.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 878(30), 3134-3142 (2010-10-20)
Quantitative methods using LC-MS/MS allow achievement of adequate sensitivity for pharmacokinetic studies with clopidogrel; three such methods, with LLOQs as low as 5 pg/mL, were developed and fully validated according to the well established FDA 2001 guidelines. The chromatographic separations
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| 51672-U | 04061838530219 |
| V900670-1G | 04061825859668 |
| T90344-25G | 04061837380433 |
| W421501-100G | 04061834406631 |
| W421501-25G | 04061835567584 |
| W421501-SAMPLE | 04061834357148 |
| V900670-5G | 04061832294933 |
| T90344-5G | 04061837380488 |
| 80345-100MG | 04061832974736 |